Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction

NCT03877224 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03877224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03877224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 4, 2019
Completion date
July 9, 2020
Enrollment
504 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction (hfpef)